J.P. Morgan’s healthcare analyst Cory Kasimov weighed in today with a few insights on Juno Therapeutics Inc (NASDAQ:JUNO), after the cancer-immunotherapy company presented updated data from its JCAR015 in ALL and JCAR014 in NHL. The clinical data results were presented in an oral presentation today at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Kasimov noted, “On the former, the data updates were largely incremental with response rates/safety being generally in-line with what we have seen from previous updates from this trial; continued consistency in this data is encouraging ahead of a multi-center Phase 2 trial start around mid-year, which could serve as the basis for approval. Perhaps more interesting was the update on JCAR014 – despite the fact that JUNO does not intend to move it forward into registration trials – as the presentation highlighted the effect of an optimized lymphodepletion regimen.”

“The discussant (Dr. Marco Davila, Vanderbilt) highlighted that data, indicating it may be necessary to refine pre-conditioning regimens based on indication. He also highlighted the potential of checkpoint inhibitors + CAR-T cells (which we have heard a lot from KOLs over the last few months), noting that the relatively limited (albeit early) efficacy we have seen thus far in solid tumors may be solved by the combination.”, the analyst added.

The analyst rates Juno Therapeutics shares an Overweight with a price target of $66, which represents a potential upside of 24% from where the stock is currently trading.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Cory Kasimov has a total average return of 14.9% and a 64.8% success rate. Kasimov has a 4.8% average return when recommending JUNO, and is ranked #194 out of 3610 analysts.


JUNO Chart